Trials / Completed
CompletedNCT01290861
Cognitive Assessment Battery (CAB) Beta Study
Cognitive Assessment Battery (CAB)Beta Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 255 (actual)
- Sponsor
- CHDI Foundation, Inc. · Academic / Other
- Sex
- All
- Age
- 25 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The overall objective of this study is to identify a 60 minute cognitive battery, for subsequent use in clinical trials, that detects cognitive deficits in early HD and late pre-manifest HD compared to controls, and that has a potential to show drug induced improvements.
Detailed description
Huntington's disease (HD) is an autosomal dominant genetic disease which typically manifests beginning in adulthood in the form of movement symptoms, cognitive decline, and psychiatric changes. The proposed research is undertaken in collaboration with CHDI Foundation, Inc., a not for profit organization dedicated to finding treatments for HD. CHDI's goal is to develop or help to develop both symptomatic and disease modifying treatments for HD. To enable future therapeutic trials, CHDI has sponsored several prospective, longitudinal, observational biomarker studies of pre-manifest and early HD with the goal of determining which combination of measures is the most sensitive for detecting changes over the natural progression of pre-manifest and early HD. These and other studies have demonstrated a progressive decline in cognitive function in patients with the huntingtin gene mutation beginning in the pre-manifest period and progressing throughout the course of the disease. These findings support the use of cognitive measures as endpoints in future therapeutic clinical trials. CHDI is committed to the development of a cognitive assessment battery for use in HD therapeutic trials. There will be paper and pencil and computerized cognitive tests given over a six week period to non-HD control subjects, pre-manifest HD and early manifest HD subjects.
Conditions
Timeline
- Start date
- 2011-02-01
- First posted
- 2011-02-07
- Last updated
- 2012-08-03
Locations
20 sites across 4 countries: United States, Australia, Canada, United Kingdom
Source: ClinicalTrials.gov record NCT01290861. Inclusion in this directory is not an endorsement.